NCT01705990View on ClinicalTrials.gov

Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2015

Conditions
HIV Infections
Interventions
BIOLOGICAL

SeV-G(NP) (0.2mL, 2x10^7 CIU)

Delivered intranasally by drops

BIOLOGICAL

SeV-G(NP) (0.2mL, 2x10^8 CIU)

Delivered intranasally by drops

BIOLOGICAL

Ad35-GRIN (0.5mL)

(1x10\^10 vp) Delivered intramuscularly by standard syringe and needle injection

Trial Locations (3)

Unknown

Kenya AIDS Vaccine Initiative, Nairobi

Project San Francisco, Kigali

St. Stephen's Centre, London

All Listed Sponsors
lead

International AIDS Vaccine Initiative

NETWORK

NCT01705990 - Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers | Biotech Hunter | Biotech Hunter